Sander Croes

930 citations

46 papers · 687 indexed · h-index 15

Transplantation top 10%
Clinical Biochemistry top 10%
Infectious Diseases top 10%
- Antimicrobial Resistance in Staphylococcus 6
Hematology
- Chronic Myeloid Leukemia Treatments 6
Pharmacology
- Antibiotics Pharmacokinetics and Efficacy 7
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 22
Oncology
- Lung Cancer Research Studies 7
- HER2/EGFR in Cancer Research 5
Genetics
- Chronic Lymphocytic Leukemia Research 6
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 4

Co-authors: Ellen E. Stobberingh Cees Neef Patrick S. Beisser Ruud H. Deurenberg Kris Stevens Leo Stolk Léo H. Koole Menno L. W. Knetsch
Cited by: Transplantation Clinical Biochemistry Infectious Diseases
Journals: Targeted Oncology (3 papers)Therapeutic Drug Monitoring (3 papers)Biomedical Chromatography (3 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Sander Croes

44 papers receiving 671 citations

Peers

Countries citing papers authored by Sander Croes

Since Specialization

Citations

This map shows the geographic impact of Sander Croes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sander Croes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sander Croes more than expected).

Fields of papers citing papers by Sander Croes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sander Croes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sander Croes. The network helps show where Sander Croes may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sander Croes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sander Croes Line = papers co-authored together Sander Croes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat The Journal of Clinical Pharmacology ·David E.J. Jones,Yurong Guan,Sander Croes,Robin M.J.M. van Geel,Lizza Hendriks,Daan J. Touw,Jos G. W. Kosterink,Jasper Stevens,Thijs H. Oude Munnink,(unknown)	2025	0
2	Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan Targeted Oncology ·Dirk Jan A. R. Moes,Jeroen J. M. A. Hendrikx,Henk‐Jan Guchelaar,Ron H.J. Mathijssen,Jurriaan Bakker,Vincent O. Dezentjé,J W Rose,Nielka P. van Erp,Egbert F. Smit,Michel M. van den Heuvel,Thijs H. Oude Munnink,Lampis R,Sander Croes,Judith R. Kroep,J. Zwaveling,Rob ter Heine	2024	1
3	Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer British Journal of Cancer ·You-Sang 윤유상Yoon,M. W. von Düben,Lizza Hendriks,Kristien Winckers,Yvonne Henskens,Jenneke Leentjens,Michel M. van den Heuvel,Rob ter Heine,Sander Croes,Berber Piet,Robin M.J.M. van Geel	2024	1
4	Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC Journal of Thoracic Oncology ·Hossein Farahini,Beverly A. McMaster,Jelena M. Josijević Mitić,刘兴远,بدر الديحاني,Opeyemi Ebenezer Agboola,Т Д Скуднова,杨留栓,Marthe S. Paats,Idris Bahce,Sander Croes,Lizza Hendriks,Anthonie J. van der Wekken,Anne‐Marie C. Dingemans,Alwin D. R. Huitema,Ron H. N. van Schaik,Ron H.J. Mathijssen,G. Veerman	2024	1
5	Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC JTO Clinical and Research Reports ·You-Sang 윤유상Yoon,G. Veerman,Hestia Zephyrine Peppé,Yurong Guan,Mary Kirkness,René J. Boosman,Ron H.J. Mathijssen,Vivianne C. G. Tjan‐Heijnen,Johanna H. M. Driessen,Bonilla Chumbi,Egbert F. Smit,Anne‐Marie C. Dingemans,Robin M.J.M. van Geel,Sander Croes,Lizza Hendriks	2024	2
6	Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer International Journal of Cancer ·مسعود میرزائی,G. Veerman,Yasuo KOGA,You-Sang 윤유상Yoon,Mary Kirkness,Pengfei Qiu,Bonilla Chumbi,Marthe S. Paats,Vivianne C. G. Tjan‐Heijnen,Cor van der Leest,Anne‐Marie C. Dingemans,Ron H.J. Mathijssen,E.M.W. van de Garde,Patrick C. Souverein,Johanna H. M. Driessen,Lizza Hendriks,Robin M.J.M. van Geel,Sander Croes	2023	7
7	Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs Journal of Chromatography B ·Yurong Guan,Xin ru Zhou,You-Sang 윤유상Yoon,Leo Stolk,Lizza Hendriks,Sander Croes,Robin M.J.M. van Geel	2023	4
8	Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer EClinicalMedicine ·G. Veerman,René J. Boosman,Hestia Zephyrine Peppé,Esther Oomen‐de Hoop,Anthonie J. van der Wekken,Idris Bahce,Lizza Hendriks,Sander Croes,Mary Kirkness,Evert de Jonge,Stijn L.W. Koolen,Neeltje Steeghs,Ron H. N. van Schaik,Egbert F. Smit,Anne‐Marie C. Dingemans,Alwin D. R. Huitema,Ron H.J. Mathijssen	2023	7
9	1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels Annals of Oncology ·مسعود میرزائی,Mariko SONODA,Yasuo KOGA,You-Sang 윤유상Yoon,Pengfei Qiu,A S Poorvika,Ron H.J. Mathijssen,Anne‐Marie C. Dingemans,Vivianne C. G. Tjan‐Heijnen,Bas Peters,Patrick C. Souverein,Johanna H. M. Driessen,Lizza Hendriks,Robin M.J.M. van Geel,Sander Croes	2022	1
10	Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial Lung Cancer ·مسعود میرزائی,You-Sang 윤유상Yoon,Lizza Hendriks,Bonilla Chumbi,A.A. Ayu Istri Laksemana Dewi,Egbert F. Smit,Anne‐Marie C. Dingemans,Robin M.J.M. van Geel,Sander Croes	2022	12
11	Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial Cancer Chemotherapy and Pharmacology ·J W Rose,René J. Boosman,Jacobus A. Burgers,Alwin D. R. Huitema,Anne‐Marie C. Dingemans,Hieronymus J. Derijks,David M. Burger,Berber Piet,Lizza Hendriks,Bonne Biesma,Filip Ccaron ulo,Daphne W. Dumoulin,Sander Croes,Ron H.J. Mathijssen,Michel M. van den Heuvel,Rob ter Heine	2022	0
12	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. The Breast ·JOSE PRASOBH M. J.,Sandra M. E. Geurts,Claude Lafleur,Sander Croes,Birgit E. P. J. Vriens,Franchette W.P.J. van den Berkmortel,M. Wouter Dercksen,Agnès J. van de Wouw,Manon J. Pepels,Margaret M. Strand,D.J.A. Lobbezoo,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	2019	1
13	Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine Journal of Pharmaceutical and Biomedical Analysis ·Rixt A. Wijma,K. Hoogtanders,Sander Croes,Johan W. Mouton,Roger J. M. Brüggemann	2019	14
14	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study Targeted Oncology ·JOSE PRASOBH M. J.,Rutger H.T. Koornstra,Johanna H. M. Driessen,Bas van Vlijmen,Sander Croes,Stein Schalkwijk,Angela Colbers,Winald R. Gerritsen,David M. Burger,Frank de Vries,Nielka P. van Erp	2018	4
15	Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors The Oncologist ·Maikel Verduin,Jaap Zindler,Elias Tadesse,Rob L. H. Jansen,Sander Croes,Lizza Hendriks,Daniëlle B. P. Eekers,Ann Hoeben	2017	20
16	Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer European Journal of Clinical Pharmacology ·Annelieke E.C.A.B. Willemsen,JOSE PRASOBH M. J.,Xin ru Zhou,Roger J. M. Brüggemann,Sander Croes,Carla M.L. van Herpen,Nielka P. van Erp	2017	21
17	Vancomycin Dosing in Neutropenic Patients PLoS ONE ·Kevin Mayall,Sander Croes,Cees Neef,Cathrien A. Bruggeman,Leo Stolk,Annelies Verbon	2014	22
18	Antimicrobial and Anti-Thrombogenic Features Combined in Hydrophilic Surface Coatings for Skin-Penetrating Catheters. Synergy of Co-embedded Silver Particles and Heparin ACS Applied Materials & Interfaces ·Sander Croes,Ellen E. Stobberingh,Kris Stevens,Menno L. W. Knetsch,Léo H. Koole	2011	29
19	Hydrophilic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters Biomaterials ·Kris Stevens,Sander Croes,Rinske Boersma,Ellen E. Stobberingh,C. van der Marel,Frederik H. van der Veen,Menno L. W. Knetsch,Léo H. Koole	2010	87
20	Diminishedin vitroantibacterial activity of oxacillin against clinical isolates of borderline oxacillin-resistantStaphylococcus aureus Clinical Microbiology and Infection ·Sander Croes,Brooke Helmick,Hardian Rifanza,Cees Neef,R. H. Deurenberg,Ellen E. Stobberingh	2009	1

About Sander Croes

Sander Croes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology, having authored 46 papers that have together received 687 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (7 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Antimicrobial Resistance in Staphylococcus (6 papers), Chronic Myeloid Leukemia Treatments (6 papers), HER2/EGFR in Cancer Research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). The work is most often cited by research in Transplantation (39 citations), Clinical Biochemistry (61 citations) and Infectious Diseases (151 citations). Sander Croes has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Ellen E. Stobberingh, Cees Neef, Patrick S. Beisser, Ruud H. Deurenberg, Kris Stevens, Leo Stolk, Léo H. Koole, Menno L. W. Knetsch, Frank de Vries and Roger J. M. Brüggemann. Their work appears in journals such as Targeted Oncology, Therapeutic Drug Monitoring, Biomedical Chromatography, Lung Cancer and Journal of Pharmaceutical and Biomedical Analysis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact